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Summary Early detection of relapse has been advocated to improve survival in children with recurrent medulloblastoma. However, the
prognostic factors and the longerterm outcome of these patients remains unclear. Pattern of recurrences were analysed in three consecutive
protocols of the Societe Frangaise d'Oncologie Pediatrique (1985-91). A uniform surveillance programme including repeated lumbar
puncture combined with computerized tomography (CT) or magnetic resonance imaging (MRI) scan was applied for all registered patients.
Forty-six out of 116 patients had progressive or recurrent disease. The median time from diagnosis to recurrence was 10.5 months and 76%
relapses occurred during the first 2 years. Seventeen patients had asymptomatic relapses that were detected by the surveillance protocol.
Forty-one patients were treated at time of progression. Twenty-three responded to salvage therapy and 11 achieved a second complete
remission. The median survival time after progression was 5 months (<1-41 months), and only two patients remained alive at time of follow-
up. Length of survival is primarily related to some specific patterns of relapse (time from diagnosis to recurrence, circumstances of relapse,
extent of relapse) and to the response to salvage therapy. No evidence of long-term benefit appeared from any form of treatment.
Keywords: medulloblastoma; relapse; prognosis; salvage therapy
Survival rate in medulloblastoma is now around 60% at 10 years
(Evans et al, 1990; Bailey et al, 1995; Gentet et al, 1995). Thus,
40% of children will develop recurrent disease despite surgery,
chemotherapy and radiotherapy. The prognosis of these patients
has in the past been dismal, with only anecdotal reports describing
prolonged survival after relapse (Miyagami et al, 1993; Mahoney
et al, 1996). Ithas been suggested thatearly identification ofrecur-
rence was associated with a longer survival (Mendel et al, 1996).
Over the last years, the value of surveillance scanning in children
with medulloblastoma has generated tremendous interest and
controversy (Torres et al, 1994; Friedman and Kun, 1995;
Steinbok et al, 1996). There are several reasons why this debate
remains open. First, the potential benefit ofsuch surveillance scan-
ning programmes has to be balanced against its economical and
psychological impact. Second, differences in survival may reflect
inherent differences in tumour aggressiveness rather than the
result of earlier detection. Finally, other independent factors may
influence the outcome of children with recurrent medullo-
blastoma. The aim ofthis study was to determine the factors influ-
encing the length of survival in an unselected group of children
registered in three consecutive cooperative protocols of the
Societe Fran,aise d'Oncologie Pediatrique (SFOP).
Received 11 April 1997
Revised 1 July 1997
Accepted25 September 1997
Correspondence to: E Bouffet, Institute of Child Health, Bristol Royal Hospital
for Sick Children, St Michael's Hill, Bristol BS2 8BJ, UK
PATIENTS AND METHODS
One-hundred and sixteen patients aged less than 20 years were
registered in the M7, M8 and M9 protocols, three consecutive
protocols for medulloblastoma of the SFOP. Eleven institutions
participated.
All patients underwent craniotomy with removal of as much
disease as possible. The pathological diagnosis of medullo-
blastoma was mandatory before initiation of the protocol. Initial
staging procedure included clinical examination, review of the
operative notes, cranial computerized tomography (CT) or
magnetic resonance imaging (MRI) scan at day 20 after surgery,
and CSF examination at day 21 at time of myelogram. Patients
were classified in two groups: high-risk patients with either brain
stem involvement, incomplete resection or metastasis and low-risk
patients with localized disease and complete resection. Thirty-
three ofthe 116 patients had initially metastatic disease.
The M7 protocol (1985-88) (Gentet et al, 1995) included two
courses of the '8 in 1' regimen (Pendergrass et al, 1987) on day 8
and day 21 after surgery. High-dose methotrexate (12 g m-2) with
subsequent folinic acid rescue was given at day 35 and 42. Four
additional courses of '8 in 1' were given once monthly after radia-
tion therapy for high-risk patients. The M8 protocol (1988-89)
included three courses of '8 in 1, before radiation therapy and three
additional courses of '8 in 1F after radiation therapy for high-risk
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patients. The M9 protocol (1989-91) included six courses of '8 in
1' followed by radiation therapy for both low-risk and high-risk
patients. Radiation was either initiated during the chemotherapy,
overlapping with the two high-dose methotrexate courses in the
M7 protocol, after three courses of '8 in 1' in the M8 protocol or
after six courses of '8 in 1, in the M9. Radiation was administered
to the cranial field at a daily dose of 1.8 Gy with five weekly frac-
tions up to a recommended dose of 27 Gy. A 27-Gy boost was
given to theposterior fossa. Spinal irradiation was delivered with a
posterior field at the same fractionation, up to 35 Gy. An addi-
tional 10-Gy boost was given locally in the case ofspinal or supra-
tentorial metastases.
All patients were followed clinically during and after treatment.
CT or MRI scan of the head with and without administration of
contrast material, was obtained 2 months after the completion of
the radiotherapy, and then every 4 months during the first 2 years
unless additional examinations were indicated clinically. The
scans were then repeated at 6 monthly intervals. CSF was exam-
ined 2 months after the completion of radiotherapy, every 2
months during the first year, and every 4 months during the second
year. Progression was defined as any new lesion detected in any of
the examinations. A complete restaging (CSF examination, CT
scan or MRI of the brain, and myelogram or MRI of the spinal
axis) was performed forrelapsing patients. Failures were analysed
in two different ways: (a) according to the site into local, distant
and combined relapses; and (b) according to the extent they were
classified as 'isolated' when the staging revealed a single site of
progression, and 'combined' in all other situations. Over this
period, guidelines for salvage therapy were based on the current
SFOP protocols, i.e. phase II studies of ifosfamide or etoposide
and carboplatin as described previously (Chastagner et al, 1993;
Gentet et al, 1994), and high-dose chemotherapy followed by
autologous bone marrow rescue for responding patients. Sixty-
eight patients were treated according to the M7 protocol, 19
according to the M8 and 29 according to the M9. Thirty-three out
of the 116 patients had initially metastatic disease.
We examined the following factors for prognostic significance:
age atdiagnosis, sex, initial staging, site offailure, time fromdiag-
nosis to relapse, patterns of detection and response to salvage
therapy. For all the variables examined, the results are reported in
terms of survival. Survival was measured from the time ofrelapse
to the date of death or last follow-up. Survival curves were drawn
using the Kaplan and Meiermethod (Kaplan and Meier, 1958). As
nearly all patients died of progression, length of survival rather
than survival was considered with regard to statistical analysis. In
the univariate analysis theprognostic factors were comparedusing
the log-rank test. Multivariate analysis was performed using the
Cox proportional hazard model. Statistical analyses were
conducted according to the procedure of the BMDP package
(BMDP Statistical Software, Los Angeles, CA, USA).
RESULTS
Patterns of recurrences
The median follow-up for recurrence-free patients is 102 months.
Forty-six patients relapsed. The age and sex of patients with and
without recurrence were similar. Considering the disease extent at
the time ofinitial diagnosis, 23 patients had metastatic disease and
23 had localized disease. Relapses occurred within a median time
of 315 days from surgery, ranging from 41 days to 81 months.
Table 1 Total number of sites in 45 relapsing patients and distribution of
sites in 22 patients with isolated site of relapse
Total Isolated
Local 20 10
CSF 20 4
Spinal 15 0
Supratentorial 19 8
Extraneural 3 0
Number of occurrences 77 22
CSF, cerebrospinal fluid.
There was no significant difference between the timing ofrelapse
between the three protocol groups. Twenty-five patients (54%) had
tumour recurrence during the first year after diagnosis, ten (22%)
during the second year, three during the third year, four during the
fourth year and three later on. Overall, 76% of recurrences
occurred during the first 2 years. Six patients developed progres-
sive disease during treatment. Subclinical recurrences were
detected in 17 patients (37%) during surveillance procedures at a
median time of 15 months from diagnosis (mean 21 months, range
5-30 months). Clinical recurrences occurred earlier, with a median
timing of 9 months from diagnosis (mean 17.5 months, range
1.5-81 months), although this difference was not statistically
significant (P = 0.41). Extensive restaging was performed in 42
out of the 46 patients, but sites of relapse were reported and
analysed in 45 patients, three patients having had incomplete
investigations (Table 1). Local relapse was reported in ten patients,
distant relapse in 25 patients and local + distant in ten patients.
Twenty-two patients had isolated relapses: ten in the primary
tumour site, eight in the supratentorial area and four had isolated
CSF relapse. Twenty-three patients had a combined relapse. This
included posterior fossa in ten, CSF in 16, supratentorial area in
11, spinal axis in 15 and systemic metastases in three patients.
Treatment of relapse
Treatment at time of relapse varied according to each institution,
taking into account the potential for resection or reirradiation, and
the wishes of the family. Treatment modalities are summarized in
Table 2. Five patients received only steroids and analgesics. Seven
patients had an attempt to excisional surgery for local (four
patients), supratentorial (two patients) or spinal (one patient)
relapse. Eight received radiotherapy. Two patients with early
progression during sandwich therapy received craniospinal radio-
therapy, fourhad a supratentorial boost (including two patients after
surgical removal), one received a 15-Gy spinal reirradiation, and
one patient with a local relapse had radiosurgery using 'gamma-
knife'. Thirty-six patients were treated using chemotherapy.
Twenty-three of them (64%) received etoposide and carboplatin as
first- or second-line salvage treatment. Other regimens included
etoposide and cyclophosphamide, '8 in 1', MOPP, etoposide and
cisplatin, or ifosfamide. Response to chemotherapy was assessed
according to the SIOP criteria (Gnekow, 1995). Eighteen patients
(50% of chemotherapy-treated patients) achieved partial or
complete response with chemotherapy. Nine responding patients
(two complete and seven partial responders) received high-dose
chemotherapy followed by bone marrow rescue. Regimens for high
dose chemotherapy were either BCNU, carboplatin and melphalan
(fourpatients), etoposide, carboplatin and melphalan (threepatients)
oretoposide and thiotepa (two patients).
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Table 2 Treatment modalities and response to salvage therapy according to the type of recurrence (among 45 patients with reported sites)
Number of Patients Chemotherapy Surgery Radiotherapy HDC Response(%)a
patients treated
Local 10 10 9 4 1 1 6 (60)
Distant 10 8 8 1 2 4 3 (37)
Local+distant 25 23 19 2 5 4 13 (56)
Combined 23 20 18 1 4 4 7 (35)
Isolated 22 21 18 6 4 5 15 (71)
HDC, high-dose chemotherapy. aPercentage according to the number of treated patients.
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Figure 1 Overall survival in months from time of relapse (n
Overall, among 41 patients treated at time ofreli
patients achieved a second complete remission, eigl
partial remission, and four had a transient resp
progression-free survival was 11 months for respoi
Three patients had stable disease, and 16 progressed
ment. One responding patient died of toxicity a
chemotherapy.
Outcome
Forty-four patients died. The median survival time
5 months (Figure 1). Two patients remain alive, onl)
free. Thirteen patients survived over 1 year after tumour recur-
rence. Among these 13 patients, ten had isolated relapses: six (out
of eight) with supratentorial relapse, three (out of four) with
isolated CSF relapse, and one (out of ten) with local relapse.
Among the prognostic factors analysed, age, sex, initial staging
and location of relapse (local, distant, local + distant) were not
significant (Tables 3 and 4). The 23 patients relapsing beyond 315
days after diagnosis had alonger survival than the 23 patients with
early relapses. Patients with relapses detected by surveillance
scanning had a longer survival than patients with symptomatic
relapse (Figure 2). Patients with isolatedrelapse had a significantly
35 42 longer survival than patients with combinedrelapse (Figure3). The 35 42
median survival time for the 12 patients with either isolated CSF
or isolated supratentorial failures was 17.8 months vs 4.7 months
= 46 patients) for the 34 other patients (P = 0.00004). Patients with isolated
relapses were more likely to respond to salvage therapy (response
rate: 71% vs 35%, P = 0.03). Patients responding to salvage
apse, 11(27%) therapy had a significantly better survival than non-responders.
it had a second Survival time did not differ between carboplatin and non-carbo-
ionse. Median platin-containing regimens (P = 0.42). Patients treated with high-
nding patients. dose chemotherapy had a median survival of 14.7 months, which
d despite treat- did not significantly differ from patients responding to conven-
fter high-dose tional therapy (P = 0.78).
We analysed the effects ofclinical parameters and treatment in a
multivariate analysis of the five most significant factors (i.e. time
to relapse, circumstances of relapse, extent of relapse, radiation
therapy and response to treatment). The extent of relapse and
from relapse is response to salvage therapy were the only independent factors for
(one is disease theprediction ofthe length ofsurvival.
Table 3 Univariate and multivariate analysis of survival according to clinical variables and treatment modalities
Univariate multivariate
analysis analysis
Variable P p
Age (<6/>6) 0.59 NS
Sex 0.30 NS
Initial staging (localized/metastatic) 0.28 NS
Time to relapse (<315 days/>315 days) 0.004 NS
Surveillance relapse/clinical relapse 0.0008 NS
Local/distant/local+distant relapse 0.41 NS
Isolated/combined relapse 0.003 0.0027
Treatment modality
Radiotherapy 0.02 NS
Surgery 0.08 NS
BMT 0.19 NS
Response to treatment 0.000001 <0.0001
BMT, bone marrow transplantation.
British Journal ofCancer(1998) 77(8), 1321-1326
..
0CancerResearch Campaign 19981324 EBouffet etal
Table 4 Median survival time by subgroup
Variable Patient Median Variable Patient Median
number survival number survival
<315 days 23 10.5 >315 days 23 4.5
Subclinical 17 13.7 Symptomatic 29 4.3
Isolated 22 11.6 Combined 24 4.4
RTa 8 16.5 No RTa 33 5.7
BMTb 9 14.7 Response/no BMTb 14 10.5
Respondersa 23 11.5 NR/stablea 19 4.3
,t.
1 e; I';
0.
aOnly 41 patients treated; bamong 23 responding patients. RT, radiotherapy; BMT, bone marrow transplantation. NR, non-responders.
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Figure 2 Survival according to circumstances of relapse (-) symptomatic,
29 patients; (--- -) surveillance relapse, 17 patients
DISCUSSION
Several studies have analysed the patterns of relapse in medullo-
blastoma (Silverman and Simpson, 1982; Wara et al, 1994).
However, little is known about the outcome and the factors influ-
encing survival of relapsing patients, and most published data
relate to selected cases or pilot studies of salvage therapies. Our
study analyses an unselected population from time of recurrence.
Its weakness is to analyse retrospectively patients treated in a
heterogenous way. However, no patient with recurrent tumour was
excluded from analysis. The 6 years follow-up from last registra-
tion allows some conclusions to be drawn.
The median time from initial diagnosis to progression does not
differ from previous reports and approaches 1 year (Evans et al,
1990; Wara et al, 1994; Bailey et al, 1995; Gentet et al, 1995).
Most of the relapses (76%) occurred during the first 2 years after
diagnosis. In the present study, the overall 7-year progression-free
survival in these three consecutive protocols is 60%. This means
that, in our experience, the 5-year survival of patients who are
alive recurrence-free at 2 years is 90%. Three relapses occurred
after 4 years. Similar late recurrences have been reported previ-
ously and account for 2-10% oftreatment failures in medulloblas-
toma (Latchaw et al, 1985; Lefkowitz et al, 1988). Regardless of
the circumstances of detection, the disease-free time correlated
positively with survival time after recurrence. Such a result is in
accordance with other paediatric and adult malignancies (Elson et
al, 1988; Grundy et al, 1989; Leivonen and Kalima, 1991).
In our study, 17 (37%) of the patients had subclinical relapses
detected on surveillance imaging orby lumbar puncture performed
during the follow-up. This incidence ranges between Torres et al
Figure 3 Survival according to the extent of the disease at time of relapse
(-) single site of relapse, 22 patients; (--- -) multiple sites, 23 patients
(1994) (17%) and Mendel et al (1996) (76%). This might be due to
some differences in the timing of surveillance scanning, and the
use of different procedures of surveillance such as CT scan, MRI
scan or repeated lumbar punctures. There has been some contro-
versy about the role of surveillance scanning and guidelines for
surveillance remain controversial in medulloblastoma. A gain in
survival in patients with subclinical detection has been reportedby
some authors (Friedman and Kun, 1995; Mendel et al, 1996).
However, other authors argue that the outcome is uniformly poor
regardless of the circumstances of detection (Torres et al, 1994;
Steinbok et al, 1996). Such differences in clinical presentation
have also been described in newly diagnosed medulloblastoma
patients, larger tumours and seeding being associated with a
shorter onset of symptoms (Halperin and Friedman, 1996). This
suggests that thebiology ofthe tumourmight influence the clinical
presentation of relapse and its detection. In our experience,
univariate analysis points out a longer survival time for patients
with subclinical relapse. However, the multivariate analysis
weakens this significance and highlights both the importance of
the type ofrelapse and the response to salvage treatment. It is still
not certain that surveillance scanning may benefit patients with
medulloblastoma and for the same reasons the role of follow-up
CSF sampling remains debatable.
The pattern of relapse influences the outcome. Classically,
relapses are described as local, distant and local + distant relapses.
No difference in outcome is observed in this study using this
classification. Our proposal to divide failures into isolated vs
combined relapses provides additional information. This is partic-
ularly clear in patients with isolated CSF and supratentorial
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relapses. The former all had subclinical recurrences possibly
related to biological features of slowly growing tumours. The
latter had relapses that might be amenable to chemotherapy,
surgery or additional radiation therapy. This subgroup of patients
has a longer survival time and is likely to respond to salvage
therapy.
Medulloblastoma has proven to be chemosensitive (Finlay and
Goins, 1987). However, despite a high response rate, responses at
time of relapse are often transient. This has led to the assessment
of high-dose therapy for responding patients using various regi-
mens (Kalifa et al, 1992; Finlay et al, 1996; Mahoney et al, 1996).
The most promising results concern high-dose chemotherapy in
relapsing infants previously non-irradiated (Dupuis-Girod et al,
1996). Encouraging preliminary survival data have been reported
by Finlay (1996) with the use of high-dose chemotherapy in
patients with recurrent medulloblastoma. In this experience, chil-
dren with minimal tumour burden are the ones who benefit from
myeloablative strategies. The present series does not support the
use of high-dose chemotherapy in the small number of patients
treated by this modality. However, this study was not designed to
address this question. Survival time, although there may be a
trend, does not significantly differ between patients treated with
conventional therapy and high-dose chemotherapy. Moreover, in
this series, candidates for high-dose chemotherapy have been
selected among responding patients. High-dose chemotherapy still
remains an experimental procedure that has yet to be shown to
have any benefit over conventional chemotherapy in relapsing
patients. Scheduling that exposes tumour to more sustained levels
ofchemotherapy might be ofbenefit (Ashley et al, 1996).
Median survival time in relapsing medulloblastoma is short, and
only 25-30% of the patients survive more than 1 year. There may
be hope with new approaches such as targeted therapy (Kemshead
et al, 1992), or gene therapy (Raffel and Culver, 1994) or sequen-
tial high-dose chemotherapy. Our findings are in agreement with
Torres et al (1994), who did not find any benefit in intensive
surveillance scanning. Patterns of relapse strongly influence the
length of survival, and the role of intensive salvage therapy in
prolonging survival remains debatable. This questions the urgency
to treat patients with recurrent medulloblastoma in cooperative
protocols (rather than pilot studies for selected patients) in orderto
clarify those patients who may benefit from aggressive salvage
strategies and those for whom decent palliative care is a more
valuable alternative.
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